JP2018524338A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524338A5 JP2018524338A5 JP2017567489A JP2017567489A JP2018524338A5 JP 2018524338 A5 JP2018524338 A5 JP 2018524338A5 JP 2017567489 A JP2017567489 A JP 2017567489A JP 2017567489 A JP2017567489 A JP 2017567489A JP 2018524338 A5 JP2018524338 A5 JP 2018524338A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- ring
- optionally substituted
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 28
- 125000005843 halogen group Chemical group 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 10
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 7
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 125000005103 alkyl silyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- -1 2,4-dioxothiazolidin-5-yl Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- IFKXGBGGICSDKX-WOJBJXKFSA-N 3-[(1R,2R)-2-hydroxycyclohexyl]-7-methyl-6-[(6-methylpyridin-3-yl)methyl]-2H-1,3-benzoxazin-4-one Chemical compound O[C@H]1[C@@H](CCCC1)N1COC2=C(C1=O)C=C(C(=C2)C)CC=1C=NC(=CC=1)C IFKXGBGGICSDKX-WOJBJXKFSA-N 0.000 claims 1
- ZUCIGCGJRYHGME-GOTSBHOMSA-N 3-[(3S,4S)-4-hydroxyoxan-3-yl]-7-methyl-6-[[4-(1-methylpyrazol-3-yl)phenyl]methyl]-2H-1,3-benzoxazin-4-one Chemical compound O[C@@H]1[C@H](COCC1)N1COC2=C(C1=O)C=C(C(=C2)C)CC1=CC=C(C=C1)C1=NN(C=C1)C ZUCIGCGJRYHGME-GOTSBHOMSA-N 0.000 claims 1
- BWJHJLINOYAPEG-HOTGVXAUSA-N 8-chloro-6-[(6-chloropyridin-3-yl)methyl]-3-[(1S,2S)-2-hydroxycyclopentyl]-7-methyl-2H-1,3-benzoxazin-4-one Chemical compound ClC1=C(C(=CC=2C(N(COC=21)[C@@H]1[C@H](CCC1)O)=O)CC=1C=NC(=CC=1)Cl)C BWJHJLINOYAPEG-HOTGVXAUSA-N 0.000 claims 1
- WLYZHPHTBRFGML-OALUTQOASA-N 8-fluoro-3-[(1S,2S)-2-hydroxycyclopentyl]-7-methyl-6-[(6-pyrazol-1-ylpyridin-3-yl)methyl]-2H-1,3-benzoxazin-4-one Chemical compound FC1=C(C(=CC=2C(N(COC=21)[C@@H]1[C@H](CCC1)O)=O)CC=1C=NC(=CC=1)N1N=CC=C1)C WLYZHPHTBRFGML-OALUTQOASA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 claims 1
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 230000001713 cholinergic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 229940126027 positive allosteric modulator Drugs 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 125000005750 substituted cyclic group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015129043 | 2015-06-26 | ||
| JP2015129043 | 2015-06-26 | ||
| JP2015206797 | 2015-10-20 | ||
| JP2015206797 | 2015-10-20 | ||
| PCT/JP2016/069189 WO2016208775A1 (en) | 2015-06-26 | 2016-06-23 | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524338A JP2018524338A (ja) | 2018-08-30 |
| JP2018524338A5 true JP2018524338A5 (https=) | 2019-07-25 |
| JP6745824B2 JP6745824B2 (ja) | 2020-08-26 |
Family
ID=56799518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567489A Active JP6745824B2 (ja) | 2015-06-26 | 2016-06-23 | 複素環化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10323027B2 (https=) |
| EP (1) | EP3313836B1 (https=) |
| JP (1) | JP6745824B2 (https=) |
| KR (1) | KR20180019234A (https=) |
| CN (1) | CN107922403A (https=) |
| AU (1) | AU2016284654B9 (https=) |
| CA (1) | CA2988572A1 (https=) |
| CL (1) | CL2017003127A1 (https=) |
| CO (1) | CO2017012859A2 (https=) |
| CR (1) | CR20170568A (https=) |
| DO (1) | DOP2017000309A (https=) |
| EA (1) | EA201890152A1 (https=) |
| HK (1) | HK1248698A1 (https=) |
| IL (1) | IL256059A (https=) |
| MX (1) | MX2017016875A (https=) |
| PE (1) | PE20180500A1 (https=) |
| PH (1) | PH12017502351A1 (https=) |
| TN (1) | TN2017000508A1 (https=) |
| TW (1) | TW201710255A (https=) |
| UA (1) | UA121503C2 (https=) |
| UY (1) | UY36750A (https=) |
| WO (1) | WO2016208775A1 (https=) |
| ZA (1) | ZA201708387B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016206101A1 (en) | 2015-06-26 | 2016-12-29 | Merck Sharp & Dohme Corp. | Metallo-beta-lactamase inhibitors |
| TN2017000508A1 (en) * | 2015-06-26 | 2019-04-12 | Takeda Pharmaceuticals Co | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| EP3366679B1 (en) | 2015-10-20 | 2021-03-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP6860551B2 (ja) | 2016-03-11 | 2021-04-14 | 武田薬品工業株式会社 | 芳香環化合物 |
| EP3590936B1 (en) * | 2017-02-28 | 2021-09-01 | Takeda Pharmaceutical Company Limited | Method for producing heterocyclic compound |
| EP3612527B1 (en) | 2017-04-18 | 2022-07-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds useful as modulators of acetylcholine receptors |
| WO2018212312A1 (ja) | 2017-05-19 | 2018-11-22 | 武田薬品工業株式会社 | スクリーニング方法 |
| WO2018235838A1 (ja) | 2017-06-20 | 2018-12-27 | 武田薬品工業株式会社 | 複素環化合物 |
| CA3068209A1 (en) | 2017-06-20 | 2018-12-27 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3858823A4 (en) | 2018-09-28 | 2022-07-06 | Takeda Pharmaceutical Company Limited | Condensed-cyclic compound |
| WO2020067455A1 (ja) | 2018-09-28 | 2020-04-02 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3858828A4 (en) * | 2018-09-28 | 2022-07-06 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| KR102288434B1 (ko) * | 2018-10-18 | 2021-08-12 | 에이치케이이노엔 주식회사 | 신규한 (이소프로필-트리아졸릴)피리디닐 치환된 벤조옥사지논 또는 벤조티아지논 유도체 및 이의 용도 |
| EP3870173A4 (en) | 2018-10-24 | 2022-06-22 | Vanderbilt University | WDR5 INHIBITORS AND MODULATORS |
| US12577227B2 (en) * | 2019-06-04 | 2026-03-17 | Vanderbilt University | WDR5 inhibitors and modulators |
| CN114539035B (zh) * | 2021-03-10 | 2023-08-18 | 山东新时代药业有限公司 | 一种七氟烷的合成方法 |
| WO2025227116A1 (en) * | 2024-04-25 | 2025-10-30 | The Board Of Regents Of The University Of Texas System | Eph-ephrin tetramerization inhibitors that target a previously unknown and very high-affinity chelator-type intermolecular protein-protein interaction |
| WO2025231259A1 (en) * | 2024-05-01 | 2025-11-06 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| WO2025231260A1 (en) * | 2024-05-01 | 2025-11-06 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5538983A (en) | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
| CZ281628B6 (cs) | 1991-07-29 | 1996-11-13 | Warner-Lambert Company | Deriváty chinazolinu a farmaceutické přípravky na jejich bázi |
| IT1255179B (it) | 1992-06-26 | 1995-10-20 | Enzo Cereda | Azaciclo e azabiciclo alchiliden idrossilamine |
| US5744476A (en) | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| JP2992677B2 (ja) | 1995-06-05 | 1999-12-20 | 武田薬品工業株式会社 | 骨形成促進医薬組成物 |
| WO1998030243A1 (en) | 1997-01-08 | 1998-07-16 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| JP2002509128A (ja) | 1998-01-16 | 2002-03-26 | パーデュー・リサーチ・ファウンデーション | アルケニルジアリールメタン非ヌクレオシドｈｉｖ−１逆転写酵素インヒビタ |
| TR200002182T2 (tr) | 1998-01-27 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | İkame edilmiş aksozaherosayklil faktör xa inhibitörleri |
| JP2003529531A (ja) | 1998-11-25 | 2003-10-07 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 置換オキソアザへテロシクリルＸａ因子阻害剤 |
| SK1182002A3 (en) | 1999-07-28 | 2002-11-06 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclyl compounds |
| JP2001131173A (ja) | 1999-08-23 | 2001-05-15 | Kyorin Pharmaceut Co Ltd | 二環式複素環誘導体 |
| JP2005231995A (ja) | 1999-12-22 | 2005-09-02 | Meiji Seika Kaisha Ltd | オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物 |
| US7084126B1 (en) | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
| EP1316203A2 (en) | 2000-06-30 | 2003-06-04 | Eli Lilly And Company | Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist |
| EP1372620A2 (en) | 2001-03-15 | 2004-01-02 | Saegis Pharmaceuticals | Methods for restoring cognitive function following systemic stress |
| US20040023951A1 (en) | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
| US20030004913A1 (en) | 2001-07-02 | 2003-01-02 | Koninklijke Philips Electronics N.V. | Vision-based method and apparatus for detecting an event requiring assistance or documentation |
| US7799913B2 (en) | 2001-11-26 | 2010-09-21 | Cortex Pharmaceuticals, Inc. | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses |
| US20040044023A1 (en) | 2002-08-30 | 2004-03-04 | Marc Cantillon | Compositions and methods for treating or preventing memory impairment |
| EP1596867A4 (en) | 2003-02-19 | 2006-03-22 | Merck & Co Inc | TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR |
| AU2004226430A1 (en) | 2003-03-28 | 2004-10-14 | Acadia Pharmaceuticals Inc. | Muscarinic M1 receptor agonists for pain management |
| US20040266659A1 (en) | 2003-06-27 | 2004-12-30 | Stephen LaBerge | Substances that enhance recall and lucidity during dreaming |
| GB0504019D0 (en) | 2005-02-26 | 2005-04-06 | Astrazeneca Ab | Amide derivatives |
| JP2008537961A (ja) | 2005-04-15 | 2008-10-02 | ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ | Ｇｐｃｒモジュレーター |
| GB0516570D0 (en) | 2005-08-12 | 2005-09-21 | Astrazeneca Ab | Amide derivatives |
| US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| WO2007044937A2 (en) | 2005-10-13 | 2007-04-19 | President And Fellows Of Harvard College | Compositions and methods to modulate memory |
| HUE030390T2 (en) | 2005-12-21 | 2017-05-29 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
| GB0607949D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| GB0607952D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
| GB0607946D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US7834023B2 (en) | 2006-09-20 | 2010-11-16 | Portola Pharmaceuticals, Inc. | Substituted dihydroquinazolines as platelet ADP receptor inhibitors |
| GEP20125438B (en) * | 2007-01-03 | 2012-03-26 | Servier Lab | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses |
| WO2008113072A2 (en) | 2007-03-15 | 2008-09-18 | Board Of Regents, The University Of Texas System | Gpcr enhanced neuroprotection to treat brain injury |
| WO2009032116A1 (en) | 2007-08-29 | 2009-03-12 | Schering Corporation | 2, 3-substituted indole derivatives for treating viral infections |
| TW200924780A (en) | 2007-08-29 | 2009-06-16 | Schering Corp | 2-carboxy substituted indole derivatives and methods of use thereof |
| ATE541845T1 (de) | 2007-08-29 | 2012-02-15 | Schering Corp | 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen |
| CA2700332A1 (en) | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| JP2010540454A (ja) | 2007-09-21 | 2010-12-24 | アカディア ファーマシューティカルズ，インコーポレーテッド | ピマバンセリンと他の薬剤との併用投与 |
| MX2010005356A (es) | 2007-11-16 | 2010-05-27 | Schering Corp | Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos. |
| CA2705587A1 (en) | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
| US20110024198A1 (en) | 2008-02-19 | 2011-02-03 | Baker Hughes Incorporated | Bearing systems containing diamond enhanced materials and downhole applications for same |
| WO2010042603A1 (en) | 2008-10-08 | 2010-04-15 | Cingulate Neuro Therapeutics, Llc | Amyloid and depression |
| NZ592961A (en) * | 2008-11-20 | 2012-09-28 | Merck Sharp & Dohme | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| CA2750708A1 (en) | 2009-02-23 | 2010-08-26 | Merck Sharp & Dohme Corp. | Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators |
| WO2010102218A1 (en) | 2009-03-05 | 2010-09-10 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| EP2421366B1 (en) | 2009-04-20 | 2013-08-28 | Merck Sharp & Dohme Corp. | Heterocyclic fused cinnoline m1 receptor positive allosteric modulators |
| ES2353093B1 (es) | 2009-05-20 | 2012-01-03 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas. |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| PT3061821T (pt) | 2009-07-22 | 2019-09-05 | PureTech Health LLC | Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos |
| AU2010286683B9 (en) | 2009-08-31 | 2014-09-04 | Merck Sharp & Dohme Llc | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators |
| EP2490692B1 (en) | 2009-10-21 | 2016-11-16 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
| US8664387B2 (en) | 2009-12-14 | 2014-03-04 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone M1 receptor positive allosteric modulators |
| US8383638B2 (en) | 2009-12-21 | 2013-02-26 | Merck Sharp & Dohme | Aminobenzoquinazolinone M1 receptor positive allosteric modulators |
| US8557992B2 (en) | 2010-06-15 | 2013-10-15 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators |
| EP2588104B1 (en) | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
| WO2012047702A1 (en) * | 2010-10-04 | 2012-04-12 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
| US9549928B2 (en) | 2011-04-29 | 2017-01-24 | The University Of Toledo | Muscarinic agonists as enhancers of cognitive flexibility |
| US9284312B2 (en) * | 2011-05-17 | 2016-03-15 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators |
| WO2012170599A1 (en) | 2011-06-10 | 2012-12-13 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| JP6211509B2 (ja) | 2012-03-02 | 2017-10-11 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| CA2868026C (en) | 2012-03-23 | 2021-02-16 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| US20130289019A1 (en) | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| WO2014077401A1 (ja) | 2012-11-19 | 2014-05-22 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| JP6075408B2 (ja) | 2012-11-22 | 2017-02-08 | 株式会社デンソー | 物標検出装置 |
| CA2886139A1 (en) | 2012-12-27 | 2014-07-03 | F. Hoffmann-La Roche Ag | Comt inhibitors |
| AU2014211728B2 (en) | 2013-02-04 | 2018-05-17 | Merck Patent Gmbh | Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions |
| EP2994460B1 (en) | 2013-05-06 | 2024-12-04 | Indiana University Research and Technology Corporation | Compounds for treatment of angiogenesis-mediated diseases |
| JP6063400B2 (ja) | 2014-01-08 | 2017-01-18 | 株式会社日立ビルシステム | エレベータの異常監視装置 |
| MX373274B (es) | 2014-04-23 | 2020-04-16 | Takeda Pharmaceuticals Co | Derivados de isoindolin-1-ona con actividad de modulador alostérico positivo del receptor colinérgico muscarínico m1 para el tratamiento de la enfermedad de alzheimer. |
| EP3144308B1 (en) | 2014-05-16 | 2020-06-24 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| WO2015190564A1 (ja) | 2014-06-13 | 2015-12-17 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| TN2017000508A1 (en) * | 2015-06-26 | 2019-04-12 | Takeda Pharmaceuticals Co | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| US20180250270A1 (en) | 2015-09-11 | 2018-09-06 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| EP3366679B1 (en) | 2015-10-20 | 2021-03-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP6860551B2 (ja) | 2016-03-11 | 2021-04-14 | 武田薬品工業株式会社 | 芳香環化合物 |
| US20200188388A1 (en) | 2016-12-29 | 2020-06-18 | Rvx Therapeutics Ltd. | Methods and compositions for potentiating cns drugs and reducing their side effects |
-
2016
- 2016-06-23 TN TNP/2017/000508A patent/TN2017000508A1/en unknown
- 2016-06-23 UY UY0001036750A patent/UY36750A/es not_active Application Discontinuation
- 2016-06-23 WO PCT/JP2016/069189 patent/WO2016208775A1/en not_active Ceased
- 2016-06-23 JP JP2017567489A patent/JP6745824B2/ja active Active
- 2016-06-23 EA EA201890152A patent/EA201890152A1/ru unknown
- 2016-06-23 CR CR20170568A patent/CR20170568A/es unknown
- 2016-06-23 AU AU2016284654A patent/AU2016284654B9/en not_active Ceased
- 2016-06-23 CN CN201680048681.6A patent/CN107922403A/zh active Pending
- 2016-06-23 TW TW105119717A patent/TW201710255A/zh unknown
- 2016-06-23 MX MX2017016875A patent/MX2017016875A/es unknown
- 2016-06-23 US US15/735,418 patent/US10323027B2/en active Active
- 2016-06-23 KR KR1020187002502A patent/KR20180019234A/ko not_active Withdrawn
- 2016-06-23 UA UAA201800653A patent/UA121503C2/uk unknown
- 2016-06-23 CA CA2988572A patent/CA2988572A1/en not_active Abandoned
- 2016-06-23 EP EP16756814.6A patent/EP3313836B1/en active Active
- 2016-06-23 HK HK18108309.9A patent/HK1248698A1/zh unknown
- 2016-06-23 PE PE2017002792A patent/PE20180500A1/es unknown
- 2016-06-23 US US15/190,642 patent/US9878989B2/en active Active
-
2017
- 2017-10-31 US US15/799,379 patent/US10087150B2/en active Active
- 2017-12-03 IL IL256059A patent/IL256059A/en unknown
- 2017-12-07 CL CL2017003127A patent/CL2017003127A1/es unknown
- 2017-12-11 ZA ZA2017/08387A patent/ZA201708387B/en unknown
- 2017-12-14 CO CONC2017/0012859A patent/CO2017012859A2/es unknown
- 2017-12-18 PH PH12017502351A patent/PH12017502351A1/en unknown
- 2017-12-26 DO DO2017000309A patent/DOP2017000309A/es unknown
-
2018
- 2018-08-27 US US16/113,635 patent/US10428056B2/en active Active
-
2019
- 2019-04-25 US US16/394,762 patent/US10899752B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524338A5 (https=) | ||
| JP2007510689A5 (https=) | ||
| JP2009534386A5 (https=) | ||
| JP2017502940A5 (https=) | ||
| JP2017505762A5 (https=) | ||
| RU2012105284A (ru) | Спиро-аминосоединения, пригодные для лечения нарушений сна и лекарственного привыкания | |
| RU2015135891A (ru) | Новые производные пиразола | |
| JP2013539777A5 (https=) | ||
| PE20161400A1 (es) | Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer | |
| JP2019513778A5 (https=) | ||
| RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
| JP2019537594A5 (https=) | ||
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| RU2012102908A (ru) | Азаадамантановые производные и способы применения | |
| JP2014523851A5 (https=) | ||
| JP2008513514A5 (https=) | ||
| JP2014526435A5 (https=) | ||
| JP2010510242A5 (https=) | ||
| JP2018530591A5 (https=) | ||
| JP2020500192A5 (https=) | ||
| JP2009528284A5 (https=) | ||
| JP2014504632A5 (https=) | ||
| JP2014523400A5 (https=) | ||
| HRP20161797T1 (hr) | Spojevi 1,3-oksazolidina ili 1,3-oksazinana kao antagonisti receptora oreksina | |
| JP2014516070A5 (https=) |